HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss
HighField Biopharmaceuticals ASCO 2024 Poster Presentation Shows HFK1, a Unique Immunoliposome May Improve Clinical Outcomes over Antibody Drug Conjugates
HighField Biopharmaceuticals to Present Preclinical Data of HFG1, a Unique mRNA-based GLP-1R Agonist, for Treatment of Diabetes, at ADA’s 84th Scientific Sessions
HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting
HighField HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe
HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1
HighField Biopharmaceuticals Announces Positive Phase 1a Data of HF1K16, a new Immuno-Oncology Drug, For Patients with Recurrent and Refractory Glioma
HighField Biopharmaceuticals Announces First Patient Dosed in Phase 1b/2 Trial of HF1K16 for Recurrent and Refractory Glioma
HANGZHOU, China--(BUSINESS WIRE)--HighField Biopharmaceuticals (HighField Bio), a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced today the U.S. Food and Drug Administration has granted clearance of the company’s Investigational New Drug (IND) application for HF158K1, a drug encapsulated immunoliposome containing doxorubicin.
HANGZHOU, China--(BUSINESS WIRE)--HighField Biopharmaceuticals (HighField Bio), a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced today the publication of an abstract including preliminary data from a Phase 1a clinical trial of HF1K16 in refractory metastatic cancer patients. It was published online at the American Society of Clinical Oncology (ASCO) Annual Meeting. HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid. The ASCO meeting is June 2 – 6, 2023, at the McCormick Place, Chicago, IL.